Joel R Lexchin

Summary

Affiliation: York University
Country: Canada

Publications

  1. ncbi request reprint CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs
    Joel Lexchin
    School of Health Policy and Management, York University Ontario, Toronto, Ontario M3J 1P3, Canada
    Global Health 10:30. 2014
  2. doi request reprint Quality and quantity of information in summary basis of decision documents issued by health Canada
    Roojin Habibi
    Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
    PLoS ONE 9:e92038. 2014
  3. pmc Too few, too weak: conflict of interest policies at Canadian medical schools
    Adrienne Shnier
    Health Policy and Equity, School of Health Policy and Management, York University, Toronto, Canada
    PLoS ONE 8:e68633. 2013
  4. pmc Of money and trust in medical care redux
    Joel Lexchin
    Professor School of Health Policy and Management, Faculty of Health, York University, 4700 Keele St Toronto Ontario M3J 1P3, Canada
    Mens Sana Monogr 10:143-9. 2012
  5. pmc Canada and access to medicines in developing countries: intellectual property rights first
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada
    Global Health 9:42. 2013
  6. doi request reprint Sponsorship bias in clinical research
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada
    Int J Risk Saf Med 24:233-42. 2012
  7. pmc Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews
    Danielle Bishop
    Graduate Program in Health, York University, Toronto, Canada
    BMC Health Serv Res 13:88. 2013
  8. pmc Models for financing the regulation of pharmaceutical promotion
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto, ON M3J 1P3, Canada
    Global Health 8:24. 2012
  9. doi request reprint Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto, ON, M3J 1P3, Canada
    Sci Eng Ethics 18:247-61. 2012
  10. doi request reprint International comparison of assessments of pharmaceutical innovation
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Ontario, Canada
    Health Policy 105:221-5. 2012

Detail Information

Publications46

  1. ncbi request reprint CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs
    Joel Lexchin
    School of Health Policy and Management, York University Ontario, Toronto, Ontario M3J 1P3, Canada
    Global Health 10:30. 2014
    ..CETA will therefore negatively impact the ability of Canada to offer quality health care. ..
  2. doi request reprint Quality and quantity of information in summary basis of decision documents issued by health Canada
    Roojin Habibi
    Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
    PLoS ONE 9:e92038. 2014
    ..prescribing a new drug: 1) Do the characteristics of patients enrolled in trials match those of patients in their practice? 2) What are the details concerning the drug's risks and benefits? 3) What are the basic characteristics of trials?..
  3. pmc Too few, too weak: conflict of interest policies at Canadian medical schools
    Adrienne Shnier
    Health Policy and Equity, School of Health Policy and Management, York University, Toronto, Canada
    PLoS ONE 8:e68633. 2013
    ..An analysis of COI policies was undertaken to document the current policy environment in all 17 Canadian medical schools...
  4. pmc Of money and trust in medical care redux
    Joel Lexchin
    Professor School of Health Policy and Management, Faculty of Health, York University, 4700 Keele St Toronto Ontario M3J 1P3, Canada
    Mens Sana Monogr 10:143-9. 2012
    ..There are still multiple examples of financial COI, and although there are isolated examples of improvement, this is still an area of deep concern...
  5. pmc Canada and access to medicines in developing countries: intellectual property rights first
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada
    Global Health 9:42. 2013
    ..As a result Canada has failed in its humanitarian duty to protect the human right to health in the form of safe and low cost medicines for the people in developing countries. ..
  6. doi request reprint Sponsorship bias in clinical research
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada
    Int J Risk Saf Med 24:233-42. 2012
    ..Pharmaceutical companies fund the vast majority of the clinical research that is undertaken on medications but face a conflict of interest between producing good science and results that will enhance the sales of their products...
  7. pmc Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews
    Danielle Bishop
    Graduate Program in Health, York University, Toronto, Canada
    BMC Health Serv Res 13:88. 2013
    ..Coverage with evidence development (CED) is being employed to meet these challenges...
  8. pmc Models for financing the regulation of pharmaceutical promotion
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto, ON M3J 1P3, Canada
    Global Health 8:24. 2012
    ..However, it involves an initial outlay of money that is currently not being spent and many national governments, in both rich and poor countries, are unwilling to incur extra costs...
  9. doi request reprint Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto, ON, M3J 1P3, Canada
    Sci Eng Ethics 18:247-61. 2012
    ..What will be needed to curb and ultimately stop the bias that we have seen is a paradigm change in the way that we treat the relationship between pharmaceutical companies and the conduct and reporting of clinical trials...
  10. doi request reprint International comparison of assessments of pharmaceutical innovation
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Ontario, Canada
    Health Policy 105:221-5. 2012
    ....
  11. ncbi request reprint Harmony in drug regulation, but who's calling the tune? An examination of regulatory harmonization in health Canada
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada
    Int J Health Serv 42:119-36. 2012
    ..Harmonization could be of benefit to Canada, but the evidence to date suggests that Health Canada been harmonizing down rather than up...
  12. doi request reprint The danger of imperfect regulation: OxyContin use in the United States and Canada
    Joel Lexchin
    School of Health Policy and Management, York University and Emergency Physician, University Health Network, Department of Family and Community Medicine, University of Toronto, Toronto, Ontario
    Int J Risk Saf Med 23:233-40. 2011
    ..We then look at the association between promotion and the misuse and abuse of OxyContin in both countries. Finally, we advance specific recommendations for regulating promotion for drugs that may have a high abuse potential...
  13. ncbi request reprint Coverage with evidence development for pharmaceuticals: a policy in evolution?
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada
    Int J Health Serv 41:337-54. 2011
    ..Until these policy issues have been addressed, CED will have difficulty achieving its potential...
  14. pmc Canada's patented medicine notice of compliance regulations: balancing the scales or tipping them?
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto Ontario M3J 1P3, Canada
    BMC Health Serv Res 11:64. 2011
    ..The regulations tied the regulatory approval of generic medicines to the patent status of the original brand-name product...
  15. pmc One step forward, one step sideways? Expanding research capacity for neglected diseases
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto ON M3J 1P3, Canada
    BMC Int Health Hum Rights 10:20. 2010
    ..This conclusion is relevant not just for the most neglected diseases such as leishmaniasis but even for global diseases such as cancer and cardiovascular disease...
  16. doi request reprint Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto, ON M3J 1P3, Canada
    Health Policy 91:142-7. 2009
    ..This paper investigates the pricing strategy (perfect flat pricing, perfect monotonic pricing, intermediate) used for multiple dosage medications listed in the Ontario Drug Benefit Formulary...
  17. ncbi request reprint Medicine reimbursement recommendations in Canada, Australia, and Scotland
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto, Ontario, Canada M3J 1P3
    Am J Manag Care 14:581-8. 2008
    ....
  18. ncbi request reprint Clinical trials in Canada: whose interests are paramount?
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada
    Int J Health Serv 38:525-42. 2008
    ..If clinical trials are to serve the purpose for which they are designed, developing reliable and objective information about new drugs, then commercial interests cannot be allowed to take precedence over health interests...
  19. pmc National evaluation of policies on individual financial conflicts of interest in Canadian academic health science centers
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada
    J Gen Intern Med 23:1896-903. 2008
    ..Conflicts of interest (COI) in research are an important emerging topic of investigation and are frequently cited as a serious threat to the integrity of human participant research...
  20. pmc Is there still a role for spontaneous reporting of adverse drug reactions?
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Ont
    CMAJ 174:191-2. 2006
  21. ncbi request reprint Implications of pharmaceutical industry funding on clinical research
    Joel R Lexchin
    School of Health Policy and Management, York University, Canada
    Ann Pharmacother 39:194-7. 2005
    ..Finally, commercially funded clinical research is more likely to yield positive results than when funding comes from other sources. Possible solutions are explored...
  22. ncbi request reprint Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON M3J 1P3, Canada
    Ann Pharmacother 40:2216-22. 2006
    ..Since the early- to mid-1990s, drug companies have paid fees for a variety of activities carried out by the Therapeutic Products Directorate in Canada and the Therapeutic Goods Administration in Australia...
  23. pmc Bigger and better: how Pfizer redefined erectile dysfunction
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Ontario, Canada
    PLoS Med 3:e132. 2006
  24. pmc Commercial influence and the content of medical journals
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada
    BMJ 332:1444-7. 2006
  25. ncbi request reprint The effect of generic competition on the price of brand-name drugs
    Joel Lexchin
    Emergency Department, University Health Network, Toronto, Ont, Canada
    Health Policy 68:47-54. 2004
    ..Literature from the US has shown that brand-name manufacturers do not compete on price once generic competitors become available. This study was undertaken to investigate if this is also true in Canada...
  26. doi request reprint Qualitative research and the politics of knowledge in an age of evidence: developing a research-based practice of immanent critique
    Eric Mykhalovskiy
    York University, Toronto, ON, Canada
    Soc Sci Med 67:195-203. 2008
    ..The latter include challenges to managerial claims about neo-liberal health reform and broadening the evidentiary terrain upon which interlocutors can participate in public debate about health care restructuring...
  27. ncbi request reprint Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here?
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto
    Int J Health Serv 35:237-56. 2005
    ..The article concludes with some alternative recommendations on the future of IPRs...
  28. pmc Are drugs too expensive in Canada? Yes
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Ont
    Can Fam Physician 52:573-6, 578-81. 2006
  29. pmc Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Ont
    CMAJ 174:1120-1. 2006
  30. ncbi request reprint Effects of restrictive formularies in the ambulatory care setting
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Canada
    Am J Manag Care 8:69-76. 2002
    ..To determine the consequences of restrictive formularies in the ambulatory care setting in 4 areas: overall drug expenditures, overall healthcare spending, changes in the quality of prescribing, and health outcomes...
  31. pmc Drug withdrawals from the Canadian market for safety reasons, 1963-2004
    Joel Lexchin
    School of Health Policy and Management, York University, Emergency Department, University Health Network, Toronto, ON
    CMAJ 172:765-7. 2005
  32. ncbi request reprint Assessing the quality of drug detailing
    William Molloy
    Geriatric Research Group, McMaster University, Hamilton Health Sciences, Henderson Site, 711 Concession Street, Ontario, Canada
    J Clin Epidemiol 55:825-32. 2002
    ..64, P <.0001, presentation time, F(2, 118) = 9.98, P <.0001, pharmaceutical representative, F(4, 118) = 9.58, P <.0001, and physician rating the detail, F(109, 118) = 1.94, P <.0001...
  33. ncbi request reprint Stop the merry-go-round
    Joel Lexchin
    School of Health Policy and Management, York University Toronto, Ontario, Canada
    Healthc Pap 4:29-34; discussion 68-72. 2004
    ..A full public pharmacare plan with first-dollar coverage will increase public expenditures but reduce overall drug costs and distribute benefits more equitably...
  34. pmc Transparency in drug regulation: mirage or oasis?
    Joel Lexchin
    Emergency Department, University Health Network, School of Health Policy and Management, York University, Toronto, Ont
    CMAJ 171:1363-5. 2004
  35. pmc Rebuttal: are drugs too expensive in Canada?
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Ont
    Can Fam Physician 52:841-2, 843-5. 2006
  36. ncbi request reprint A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto, Ont, and Emergency Department, University Health Network, Canada
    Health Policy 79:214-20. 2006
    ..This study uses a convenience sample of new drugs marketed in the United States and determines how many of these products are initially unavailable in Canada and their therapeutic value...
  37. pmc Pharmaceutical industry sponsorship and research outcome and quality: systematic review
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada M3J 1P3
    BMJ 326:1167-70. 2003
    ....
  38. pmc New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?
    Joel Lexchin
    School of Health Policy and Management at York University, Toronto, Ont
    Can Fam Physician 48:1487-92. 2002
    ..To determine how many randomized controlled trials on the safety or efficacy of new drugs are published when these drugs are first marketed in Canada, and to determine the quality of the information in those trials...
  39. ncbi request reprint The secret things belong unto the Lord our God: secrecy in the pharmaceutical arena
    Joel Lexchin
    School of Health Policy and Management, York University
    Med Law 26:417-30. 2007
    ..By treating data on efficacy and safety as commercially confidential information they effectively collude with industry in denying health professionals and the public access to essential information to be able to use drugs appropriately...
  40. ncbi request reprint Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence
    Joel Lexchin
    School of Health Policy and Management at York University, Toronto, Canada
    Int J Health Serv 34:101-22. 2004
    ..Cost sharing also leads to patients foregoing essential medications and to a decline in health care status...
  41. pmc Physician awareness of drug cost: a systematic review
    G Michael Allan
    Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada, 2 Institute of Health Economics, Edmonton, Alberta, Canada
    PLoS Med 4:e283. 2007
    ..We designed this systematic review to investigate doctors' knowledge of the relative and absolute costs of medications and to determine the factors that influence awareness...
  42. pmc Poor reporting of scientific leadership information in clinical trial registers
    Melanie Sekeres
    Kunin Lunenfeld Applied Research Unit, Baycrest, Toronto, Ontario, Canada
    PLoS ONE 3:e1610. 2008
    ..Identifying those scientifically responsible for trial conduct increases accountability. The objective is to examine the proportion of registered clinical trials providing valid scientific leadership information...
  43. doi request reprint Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agencies
    Joel Lexchin
    York University, Toronto, Canada
    Soc Sci Med 70:643-7. 2010
    ..Under this model COI would be prohibited on the grounds that it might influence the outcome of regulatory decisions...